New biomarkers in T-cell lymphomas

Bisig, Bettina; Gaulard, Philippe; Leval, Laurence de

doi:10.1016/j.beha.2012.01.004

Cited by 18 publications

(16 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 46 putative OAs identified [27], B7-H4 [28], Claudin 3 [29], Hepsin [30], CD52 [31], and Desmoglein 2 [32] are Class I OAs, expressed on the plasma membrane of cancer and TME cells and therefore constitute promising targets for vaccination. Class II OAs are another group of identified OAs and includes cytokines and chemokines copiously released in the TME.…”

Section: The Urgency Of Defining the Most Promising Tme-associatedmentioning

confidence: 99%

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice

Conti

Ruiu

Barutello

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

The tyrosine kinase human epidermal growth factor receptor 2 (HER2) gene is amplified in approximately 20% of human breast cancers and is associated with an aggressive clinical course and the early development of metastasis. Its crucial role in tumor growth and progression makes HER2 a prototypic oncoantigen, the targeting of which may be critical for the development of effective anticancer therapies. The setup of anti-HER2 targeting strategies has revolutionized the clinical outcome of HER2+ breast cancer. However, their initial success has been overshadowed by the onset of pharmacological resistance that renders them ineffective. Since the tumor microenvironment (TME) plays a crucial role in drug resistance, the design of more effective anticancer therapies should depend on the targeting of both cancer cells and their TME as a whole. In this review, starting from the successful know-how obtained with a HER2+ mouse model of mammary carcinogenesis, the BALB-neuT mice, we discuss the role of TME in mammary tumor development. Indeed, a deeper knowledge of antigens critical for cancer outbreak and progression and of the mechanisms that regulate the interplay between cancer and stromal cell populations could advise promising ways for the development of the best anticancer strategy.

show abstract

Section: The Urgency Of Defining the Most Promising Tme-associatedmentioning

confidence: 99%

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice

Conti

Ruiu

Barutello

et al. 2014

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…The presence of TCR V β 16 expression confirmed the presence of clonality 13. CD 30 negativity helped rule out certain subtypes of anaplastic and cutaneous T-cell lymphomas 12 14. The partial presence of CD 57, a marker of natural killer cell maturation, might indicate a likely higher likelihood of ‘B’ symptoms and bone marrow involvement as CD 57 expression has been proposed as a prognostic marker related to immune dysfunction 15.…”

Section: Discussionmentioning

confidence: 87%

Rare case of T-cell lymphoma presenting as acute myelopathy

Samara

Havenon

2016

BMJ Case Reports

View full text Add to dashboard Cite

Acute myelopathy is a rare presentation of systemic T-cell lymphoma. We present the case of a man aged 68 years with a diffuse erythematous maculopapular rash, followed by lower extremity paresthesias and progressive lower extremity weakness. Spinal MRI showed longitudinally extensive T2 hyperintensity with diffuse contrast enhancement. An atypical clonal T-lymphocyte population was identified in cerebrospinal fluid, peripheral blood and bone marrow aspirate, indicating a malignant T-cell lymphoproliferative disorder. The patient was treated with intrathecal and systemic chemotherapy. Unfortunately, he was not responsive to chemotherapy.

show abstract

“…IRF4 is induced by mitogenic stimuli, such as antigen receptor engagement, lipopolysaccharides, and CD40 signaling [14], [15], which activate the Nuclear Factor-kappa B (NF-kB) pathway, ultimately leading to IRF4 promoter activation [16]–[18]. Despite functioning as a tumor suppressor gene in early B-cell development [11], [19], IRF4 is a well-established oncogene in multiple myeloma (MM) [20], with oncogenic implications extending to certain adult lymphomas and leukemias [13], [21]–[23]. High expression levels have been detected in chronic lymphocytic leukemia (CLL), where they have been linked to an unfavourable prognosis [24]–[27].…”

Section: Introductionmentioning

confidence: 99%

Implication of IRF4 Aberrant Gene Expression in the Acute Leukemias of Childhood

et al. 2013

View full text Add to dashboard Cite

The most frequent targets of genetic alterations in human leukemias are transcription factor genes with essential functions in normal blood cell development. The Interferon Regulatory Factor 4 (IRF4) gene encodes a transcription factor important for key developmental stages of hematopoiesis, with known oncogenic implications in multiple myeloma, adult leukemias and lymphomas. Very few studies have reported an association of IRF4 with childhood malignancy, whereas high transcript levels have been observed in the more mature immunophenotype of ALL. Our aim was to investigate the expression levels of IRF4 in the diagnostic samples of pediatric leukemias and compare them to those of healthy controls, in order to determine aberrant gene expression and whether it extends to leukemic subtypes other than the relatively mature ALL subpopulation. Quantitative real-time RT-PCR methodology was used to investigate IRF4 expression in 58 children with acute leukemias, 4 leukemic cell lines and 20 healthy children. We show that aberrant IRF4 gene expression is implicated in a variety of leukemic subtypes; higher transcript levels appear in the more immature B-common ALL subtype and in T-cell than in B-cell leukemias, with the highest expression levels appearing in the AML group. Interestingly, we show that childhood leukemia, irrespective of subtype or cell maturation stage, is characterised by a minimum of approximately twice the amount of IRF4 gene expression encountered in healthy children. A statistically significant correlation also appeared to exist between high IRF4 expression and relapse. Our results show that ectopic expression of IRF4 follows the reverse expression pattern of what is encountered in normal B-cell development and that there might be a dose-dependency of childhood leukemia for aberrantly expressed IRF4, a characteristic that could be explored therapeutically. It is also suggested that high IRF4 expression might be used as an additional prognostic marker of relapse at diagnosis.

show abstract

New biomarkers in T-cell lymphomas

Cited by 18 publications

References 106 publications

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice

Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice

Rare case of T-cell lymphoma presenting as acute myelopathy

Implication of IRF4 Aberrant Gene Expression in the Acute Leukemias of Childhood

Contact Info

Product

Resources

About